ISRCTN89754756
Completed
未知
Stage 3 Pilot Study: a decision tool to improve the management of urinary incontinence in women in the community
niversity of York (UK)0 sites150 target enrollmentMarch 18, 2011
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity of York (UK)
- Enrollment
- 150
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthcare professionals: Any healthcare professional who works in a community/primary care setting whose role involves assessment and management of urinary incontinence in women in the community. Health care professionals will be working within two primary care trusts where NHS permissions will be sought for the study to proceed
- •2\. Patients: Women who are over 18 years of age, not pregnant and have symptoms of urinary incontinence are eligible to be invited into the study.; Target Gender: Male \& Female ; Lower Age Limit 18 no age limit or unit specified
Exclusion Criteria
- •1\. Health care professionals who were involved in the intial development of the decision tool
- •2\. Patients who are under 18 years of age
- •3\. Patients who are pregnant
- •4\. Patients who are unable to give informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole.Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.MedDRA version: 14.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Parasitic Diseases [C03]EUCTR2012-005409-38-ESFundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)56
Active, not recruiting
Phase 1
Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCERPacientes con cáncer de próstata metastásico sin experiencia de quimioterapia y con elevación documentada del antígeno prostático específico (PSA) o enfermedad progresiva (EP) documentada después de tratamiento hormonal.Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 12.0Level: PTClassification code 10036909Term: Prostate cancer metastaticEUCTR2008-007969-23-ESCelgene Corporation1,015
Active, not recruiting
Phase 1
Ensayo pivotal de fase III para determinar la eficacia y la seguridad del comprimido bucodispersable de vardenafilo comparado con placebo en el tratamiento de hombres con disfunción eréctil (DE) – ensayo multicéntrico, aleatorizado, doble ciego y de dosis fija – POTENT I Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, raNdomized multi-center Trial - POTENT I - POTENT IEUCTR2008-000536-40-ESBayer HealthCare AG
Active, not recruiting
Phase 3
A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndromeFamilial Chylomicronemia SyndromeGenetic DiseasesISRCTN12904794Arrowhead Pharmaceuticals, Inc.76
Completed
Phase 3
A Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in subjects with castrate-resistant prostate cancer.prostate cancer that can't be treated surgically1003859710036958NL-OMON43687Celgene Corporation136